Wang YZ, Li JL, Wang X, Zhang T, Ho WZ. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes. World J Gastroenterol 2017; 23(32): 5895-5903 [PMID: 28932081 DOI: 10.3748/wjg.v23.i32.5895]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 28, 2017; 23(32): 5895-5903 Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5895
(-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes
Yi-Zhong Wang, Jie-Liang Li, Xu Wang, Ting Zhang, Wen-Zhe Ho
Yi-Zhong Wang, Ting Zhang, Department of Infectious Diseases, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai 200040, China
Jie-Liang Li, Xu Wang, Wen-Zhe Ho, Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, United States
Author contributions: Wang YZ, Zhang T and Ho WZ designed the research; Wang YZ and Li JL performed the research; Wang X contributed new reagents/analytical tools; Wang YZ and Zhang T analyzed the data; Wang YZ and Zhang T wrote the paper.
Supported bythe National Natural Science Foundation of China, No. 81500449; the Natural Science Foundation of Shanghai, No. 14ZR1434200; Shanghai Municipal Commission of Health and Family Planning, No. 20144Y0175; the Scientific Research Foundation for the Returned Overseas Chinese Scholars; and the State Education Ministry of China, No. 20150909-6.
Conflict-of-interest statement: The authors declare no conflict of interest associated with this manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ting Zhang, MD, PhD, Department of Infectious Diseases, Shanghai Children’s Hospital, Shanghai Jiao Tong University, 355 Luding Road, Shanghai 200040, China. zhangt@shchildren.com.cn
Telephone: +86-21-52976338 Fax: +86-21-52976338
Received: January 4, 2017 Peer-review started: January 6, 2017 First decision: March 16, 2017 Revised: March 30, 2017 Accepted: July 22, 2017 Article in press: July 24, 2017 Published online: August 28, 2017 Processing time: 235 Days and 14.4 Hours
Core Tip
Core tip: The interactions between hepatitis C virus (HCV) and the host immune system in the liver play a key role in the immunopathogenesis of HCV-induced diseases. We showed here that (-)-epigallocatechin-3-gallate (EGCG) treatment could significantly increase the poly I:C-induced expression of TLR3, RIG-I and interferon (IFN)-λ1 in JFH-1-Huh7 cells. In addition, supplementation with EGCG enhanced poly I:C-mediated viral inhibition in JFH-1-Huh7 cells at both RNA and protein levels. Further investigation of the mechanisms showed that EGCG treatment significantly enhanced the poly I:C-induced expression of IFN-regulatory factor 9 and several IFN-stimulated genes. It would be interesting to investigate the possible use of EGCG in combination with current antiviral drugs for HCV therapy.
Share the Article
Wang YZ, Li JL, Wang X, Zhang T, Ho WZ. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes. World J Gastroenterol 2017; 23(32): 5895-5903 [PMID: 28932081 DOI: 10.3748/wjg.v23.i32.5895]
